Related Experiment Video
Updated: Jun 12, 2026
10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Marginal zone lymphomas: factors that affect the final outcome.
Ali Mazloom1, L Jeffrey Medeiros, Peter W McLaughlin
1Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer
|June 16, 2010
Summary
Splenic marginal zone lymphoma (MZL) patients have a better prognosis. A new scoring system using three factors aids in predicting recurrence-free survival for extranodal MZL.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Retrospective analysis of 275 marginal zone lymphoma (MZL) patients.
- Investigated prognostic factors for MZL, focusing on extranodal subtypes.
Purpose of the Study:
- Determine prognostic factors for marginal zone lymphoma (MZL).
- Establish a prognostic scoring system for extranodal MZL patients.
Main Methods:
- Categorized 275 MZL patients into extranodal, nodal, and splenic groups.
- Analyzed clinical and laboratory factors including age, gender, B symptoms, performance score, clinical stage, serum markers (β(2)-microglobulin, LDH, albumin, hemoglobin), and autoimmune disorders.
Main Results:
- Splenic MZL showed the best prognosis (HR 0.18, P=.018).
- Elevated serum β(2)-microglobulin, B symptoms, and male gender correlated with decreased recurrence-free survival (RFS).
- A 3-tier prognostic score for extranodal MZL demonstrated significant differences in 5-year RFS (80% low-risk, 71% intermediate-risk, 44% high-risk; P=.01).
Conclusions:
- Splenic MZL patients have a superior prognosis compared to extranodal and nodal MZL.
- A novel, easily applicable prognostic scoring system was developed for extranodal MZL using three key factors.
